Summary
[Sinovac releases 2021 annual report: net profit of US$14.5 billion in global supply of new crown vaccine exceeds 2.8 billion doses]SINOVAC released its 2021 annual report, with annual sales of US$19.4 billion and net profit of US$14.5 billion in 2021. Among them, the sales in the first half of the year were 11 billion US dollars, and the sales in the second half were 8.4 billion US dollars. Selling and administrative expenses for the full year were $591.2 million and research and development expenses were $155 million. (Interface News)
SINOVAC released the 2021 annual report, with annual sales of 19.4 billion US dollars in 2021,net profit$14.5 billion. Among them, the sales in the first half of the year were 11 billion US dollars, and the sales in the second half were 8.4 billion US dollars. Selling and administrative expenses for the full year were $591.2 million and research and development expenses were $155 million.
Nearly half of last year’s sales came from the international market. So far, the global supply of Kexing’s new crown vaccine has exceeded 2.8 billion doses, of which 300 million doses have been donated domestically. In addition, the company’s Omicron variant new coronavirus inactivated vaccine was recently officially approved by the State Drug Administration to enter clinical research.
(Article source: Interface News)
